$255.00
Cagrilintide + Semaglutide Blend 10mg is a dual-peptide research blend studied for amylin and GLP-1 receptor signalling, appetite-regulation pathways, gastric-emptying models, and metabolic research. For laboratory research use only.
Cagrilintide + Semaglutide Blend 10mg, commonly referred to as CagriSema, is a dual-peptide research blend combining Cagrilintide, a long-acting amylin analogue, with Semaglutide, a GLP-1 receptor agonist. This blend is commonly studied in laboratory research involving amylin receptor signalling, GLP-1 receptor activity, appetite-regulation pathways, gastric-emptying models, glucose metabolism, and metabolic research. Novo Nordisk describes CagriSema as a fixed-dose combination of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a long-acting GLP-1 receptor agonist.
CAS No.:
Cagrilintide: 1415456-99-3
Semaglutide: 910463-68-2
Some suppliers may list different CAS numbers for cagrilintide or related salt/intermediate forms, so the batch COA should be checked before publishing.
This product is intended for laboratory research use only and is not for human consumption, clinical use, veterinary use, or diagnostic applications.
